
pmid: 37178319
pmc: PMC10281381
AbstractAntimicrobial resistance is a major obstacle for the treatment of infectious diseases and currently represents one of the most significant threats to global health. Staphylococcus aureus remains a formidable human pathogen with high mortality rates associated with severe systemic infections. S. aureus has become notorious as a multidrug resistant bacterium, which when combined with its extensive arsenal of virulence factors that exacerbate disease, culminates in an incredibly challenging pathogen to treat clinically. Compounding this major health issue is the lack of antibiotic discovery and development, with only two new classes of antibiotics approved for clinical use in the last 20 years. Combined efforts from the scientific community have reacted to the threat of dwindling treatment options to combat S. aureus disease in several innovative and exciting developments. This review describes current and future antimicrobial strategies aimed at treating staphylococcal colonization and/or disease, examining therapies that show significant promise at the preclinical development stage to approaches that are currently being investigated in clinical trials.
Staphylococcus aureus, Immunoconjugates, Drug Resistance, Mini Reviews, 610, Staphylococcal Infections/drug therapy, Drug Development, Drug Resistance, Multiple, Bacterial, 616, Humans, Adjuvants, Phage Therapy, Immunoconjugates/therapeutic use, Adjuvants, Pharmaceutic, Biological Products, Bacterial, Drug Synergism, Staphylococcal Infections, Anti-Bacterial Agents, Anti-Bacterial Agents/therapeutic use, Drug Development/trends, Pharmaceutic/therapeutic use, Biological Products/therapeutic use, Multiple, TP248.13-248.65, Biotechnology, Antimicrobial Cationic Peptides
Staphylococcus aureus, Immunoconjugates, Drug Resistance, Mini Reviews, 610, Staphylococcal Infections/drug therapy, Drug Development, Drug Resistance, Multiple, Bacterial, 616, Humans, Adjuvants, Phage Therapy, Immunoconjugates/therapeutic use, Adjuvants, Pharmaceutic, Biological Products, Bacterial, Drug Synergism, Staphylococcal Infections, Anti-Bacterial Agents, Anti-Bacterial Agents/therapeutic use, Drug Development/trends, Pharmaceutic/therapeutic use, Biological Products/therapeutic use, Multiple, TP248.13-248.65, Biotechnology, Antimicrobial Cationic Peptides
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 38 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 1% |
